These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12073178)

  • 1. Unresolved issues in the prevention and treatment of venous thromboembolism.
    Agnelli G
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():33-40. PubMed ID: 12073178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug trials that have influenced our practice in the treatment of venous thromboembolism.
    Kearon C
    Thromb Haemost; 1997 Jul; 78(1):553-7. PubMed ID: 9198214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of symptomatic venous thromboembolism: improving outcomes.
    Büller HR
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():41-8. PubMed ID: 12073179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
    Balibrea JL; Altimiras J; Larruzea I; Gómez-Outes A; Martínez-González J; Rocha E;
    Int J Surg; 2007 Apr; 5(2):114-9. PubMed ID: 17448976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing prophylaxis of venous thromboembolism.
    Turpie AG
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():25-32. PubMed ID: 12073177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thromboembolism prophylaxis in medical patients: future perspectives.
    Imberti D; Prisco D
    Thromb Res; 2005; 116(5):365-75. PubMed ID: 16122549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic events.
    Drouet L; Bal Dit Sollier C
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():21-6. PubMed ID: 15701144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts for the prevention of venous thromboembolism.
    Bramlage P; Pittrow D; Kirch W
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():4-11. PubMed ID: 15701142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolic risk and its prevention in hospitalized medical patients.
    Haas SK
    Semin Thromb Hemost; 2002 Dec; 28(6):577-84. PubMed ID: 12536351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antithrombotic drugs: potential for use in oncology.
    Levine MN
    J Clin Oncol; 2009 Oct; 27(29):4912-8. PubMed ID: 19738103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism prevention in acutely ill nonsurgical patients.
    Brophy DF; Dougherty JA; Garrelts JC; Parish RC; Rivey MP; Stumpf JL; Taylor CT; Mathis AS
    Ann Pharmacother; 2005; 39(7-8):1318-24. PubMed ID: 15941823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of venous thromboembolism in internal medicine and neurology].
    Malý J; Dulícek P; Penka M; Malý R; Gumulec J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism in cancer patients: expanding horizons.
    Bergqvist D
    Semin Thromb Hemost; 2002 Aug; 28 Suppl 3():19-23. PubMed ID: 12232819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL
    J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for venous thromboembolism in children.
    Gerotziafas GT
    Int Angiol; 2004 Sep; 23(3):195-205. PubMed ID: 15765033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
    Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
    J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.